Physician profile
Jose M Bordon
NPI 1174550701
$12,211.21
in general payments reported to CMS, 2019-2025
30 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,197 · 2020: $2,037 · 2021: $1,231 · 2022: $1,488 · 2023: $1,123 · 2024: $2,834 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,400 · Consulting Fee: $1,860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,399.90 |
| Consulting Fee | $1,860.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,390.89 | 2019-2025 | |
| Viiv Healthcare Company | $2,808.40 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Merck Sharp & Dohme LLC | $2,074.84 | 2019-2024 | Pifeltro |
| Theratechnologies INC. | $1,305.24 | 2019-2024 | Egrifta, Trogarzo |
| Janssen Biotech, INC. | $1,016.52 | 2019-2023 | Symtuza |
| Abbvie INC. | $418.03 | 2019-2025 | Ubrelvy |
| Janssen Products, Lp | $274.97 | 2019-2021 | |
| Napo Pharmaceuticals INC | $184.74 | 2019-2023 | Mytesi |
| Biohaven Pharmaceutical Holding Company Ltd. | $134.30 | 2022 | |
| Comsort, INC | $100.00 | 2019 | |
| Novo Nordisk INC | $76.53 | 2021-2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.04 | 2019-2021 | |
| Lilly USA, LLC | $62.76 | 2020-2024 | Zepbound |
| Arbor Pharmaceuticals, INC. | $37.76 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.05 | 2023 | Trintellix |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $24.44 | 2019 | |
| Dynavax Technologies Corporation | $24.20 | 2019 | |
| Amgen INC. | $23.66 | 2024 | Repatha, Otezla |
| Mylan Institutional INC. | $23.19 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.68 | 2022 | |
| Shionogi INC | $21.16 | 2024 | Fetroja |
| Exact Sciences Corporation | $18.55 | 2024 | Cologuard Collection Kit |
| Insmed, INC. | $18.20 | 2019 | |
| Hologic Sales and Service, LLC | $14.92 | 2024 | Aptima |
| Astrazeneca Pharmaceuticals Lp | $14.82 | 2019 | |
| Boston Scientific Corporation | $13.82 | 2024 | |
| Endo Pharmaceuticals INC. | $11.50 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Bordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.